JPWO2019183266A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019183266A5
JPWO2019183266A5 JP2020550748A JP2020550748A JPWO2019183266A5 JP WO2019183266 A5 JPWO2019183266 A5 JP WO2019183266A5 JP 2020550748 A JP2020550748 A JP 2020550748A JP 2020550748 A JP2020550748 A JP 2020550748A JP WO2019183266 A5 JPWO2019183266 A5 JP WO2019183266A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
chain comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550748A
Other languages
Japanese (ja)
Other versions
JP2021518142A (en
JP7393342B2 (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023238 external-priority patent/WO2019183266A1/en
Publication of JP2021518142A publication Critical patent/JP2021518142A/en
Publication of JPWO2019183266A5 publication Critical patent/JPWO2019183266A5/ja
Application granted granted Critical
Publication of JP7393342B2 publication Critical patent/JP7393342B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (96)

ヒトＳＩＲＰ－αポリペプチドの細胞外ドメインに結合する単離された抗体であって、
（ａ）配列番号１２４のアミノ酸配列を含む重鎖；及び
（ｂ）配列番号２５のアミノ酸を含む軽鎖可変（ＶＬ）ドメインを含む軽鎖
を含む抗体。 An isolated antibody that binds to the extracellular domain of a human SIRP-α polypeptide.
An antibody comprising (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 124; and (b) a light chain comprising a light chain variable (VL) domain comprising the amino acid of SEQ ID NO: 25. ヒトＳＩＲＰ－αポリペプチドの細胞外ドメインに結合する単離された抗体であって、
（ａ）配列番号５８のアミノ酸配列を含む重鎖；及び
（ｂ）配列番号２５のアミノ酸を含む軽鎖可変（ＶＬ）ドメインを含む軽鎖
を含む抗体。 An isolated antibody that binds to the extracellular domain of a human SIRP-α polypeptide.
An antibody comprising (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 58; and (b) a light chain comprising a light chain variable (VL) domain comprising the amino acid of SEQ ID NO: 25. ヒトＳＩＲＰ－αポリペプチドの細胞外ドメインに結合する単離された抗体であって、
（ａ）配列番号６２のアミノ酸配列を含む重鎖；及び
（ｂ）配列番号２５のアミノ酸を含む軽鎖可変（ＶＬ）ドメインを含む軽鎖
を含む抗体。 An isolated antibody that binds to the extracellular domain of a human SIRP-α polypeptide.
An antibody comprising (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 62; and (b) a light chain comprising a light chain variable (VL) domain comprising the amino acid of SEQ ID NO: 25. 軽鎖が、配列番号３７のアミノ酸を含むλ定常軽鎖（ＣＬ）ドメインをさらに含む、請求項１～３のいずれか１項に記載の抗体。 The antibody according to any one of claims 1 to 3, wherein the light chain further comprises a λ constant light chain (CL) domain containing the amino acid of SEQ ID NO: 37. 軽鎖が、配列番号４７のアミノ酸配列を含む、請求項１～４のいずれか１項に記載の抗体。 The antibody according to any one of claims 1 to 4, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 47. ヒトＳＩＲＰ－αポリペプチドを発現するマクロファージによるファゴサイトーシスを亢進する、請求項１～５のいずれか１項に記載の抗体。 The antibody according to any one of claims 1 to 5, which enhances phagocytosis by macrophages expressing a human SIRP-α polypeptide. ヒトＳＩＲＰ－αポリペプチドを発現する樹状細胞の活性化を亢進する、請求項１～６のいずれか１項に記載の抗体。 The antibody according to any one of claims 1 to 6, which enhances the activation of dendritic cells expressing a human SIRP-α polypeptide. ＣＤ４７を発現する腫瘍のインビボ成長を阻害する、請求項１～７のいずれか１項に記載の抗体。 The antibody according to any one of claims 1 to 7, which inhibits the in vivo growth of a tumor expressing CD47. 薬剤にコンジュゲートされる、請求項１～８のいずれか１項に記載の抗体。 The antibody according to any one of claims 1 to 8, which is conjugated to a drug. 薬剤が、免疫系を調節する部分である、請求項９に記載の抗体。 The antibody according to claim 9, wherein the drug is a portion that regulates the immune system. 薬剤が、ＣｐＧオリゴヌクレオチドを含む、請求項９又は１０に記載の抗体。 The antibody according to claim 9 or 10, wherein the agent comprises a CpG oligonucleotide. 請求項１～１１のいずれか１項に記載の抗体をコードするポリヌクレオチド。 A polynucleotide encoding the antibody according to any one of claims 1 to 11. 請求項１２に記載のポリヌクレオチドを含むベクター。 The vector containing the polynucleotide according to claim 12. 請求項１２に記載のポリヌクレオチド又は請求項１３に記載のベクターを含む宿主細胞。 A host cell comprising the polynucleotide according to claim 12 or the vector according to claim 13. 抗体が産生されるように請求項１４に記載の宿主細胞を培養することを含む、抗体を産生する方法。 A method for producing an antibody, which comprises culturing the host cell according to claim 14 so that the antibody is produced. 抗体を宿主細胞から回収することをさらに含む、請求項１５に記載の方法。 15. The method of claim 15, further comprising recovering the antibody from a host cell. 請求項１～１１のいずれか１項に記載の抗体の有効量を含む、個体のがんを治療する又は個体のがんの進行を遅らせるための医薬。 A pharmaceutical agent comprising an effective amount of the antibody according to any one of claims 1 to 11 for treating an individual's cancer or delaying the progression of the individual's cancer. 個体のがんを治療する又は個体のがんの進行を遅らせるための医薬を製造するための、請求項１～１１のいずれか１項に記載の抗体の使用。 Use of the antibody according to any one of claims 1 to 11 for producing a drug for treating an individual's cancer or delaying the progression of the individual's cancer. がんにより発現される抗原に結合する第２の抗体の有効量が個体にさらに投与される、請求項１７に記載の医薬。 17. The apparatus of claim 17, wherein an effective amount of a second antibody that binds to an antigen expressed by cancer is further administered to an individual. がんにより発現される抗原が、ＣＤ１９、ＣＤ２０、ＣＤ２２、ＣＤ３０、ＣＤ３３、ＣＤ３８、ＣＤ５２、ＣＤ５６、ＣＤ７０、ＣＤ７４、ＣＤ７９ｂ、ＣＤ１２３、ＣＤ１３８、ＣＳ１／ＳＬＡＭＦ７、Ｔｒｏｐ－２、５Ｔ４、ＥｐｈＡ４、ＢＣＭＡ、ムチン１、ムチン１６、ＰＴＫ７、ＳＴＥＡＰ１、エンドセリンＢ型受容体、メソテリン、ＥＧＦＲｖＩＩＩ、ＥＮＰＰ３、ＳＬＣ４４Ａ４、ＧＮＭＢ、ネクチン４、ＮａＰｉ２ｂ、ＬＩＶ－１Ａ、グアニル酸シクラーゼＣ、ＤＬＬ３、ＥＧＦＲ、ＨＥＲ２、ＶＥＧＦ、ＶＥＧＦＲ、インテグリンαＶβ３、インテグリンα５β１、ＭＥＴ、ＩＧＦ１Ｒ、ＴＲＡＩＬＲ１、ＴＲＡＩＬＲ２、ＲＡＮＫＬ、ＦＡＰ、テネイシン、Ｌｅｙ、ＥｐＣＡＭ、ＣＥＡ、ｇｐＡ３３、ＰＳＭＡ、ＴＡＧ７２、ムチン、ＣＡＩＸ、ＥＰＨＡ３、葉酸受容体α、ＧＤ２、ＧＤ３、及びＮＹ－ＥＳＯ－１／ＬＡＧＥ、ＳＳＸ－２、ＭＡＧＥファミリータンパク質、ＭＡＧＥ－Ａ３、ｇｐ１００／ｐｍｅｌ１７、Ｍｅｌａｎ－Ａ／ＭＡＲＴ－１、ｇｐ７５／ＴＲＰ１、チロシナーゼ、ＴＲＰ２、ＣＥＡ、ＰＳＡ、ＴＡＧ－７２、未成熟ラミニン受容体、ＭＯＫ／ＲＡＧＥ－１、ＷＴ－１、ＳＡＰ－１、ＢＩＮＧ－４、ＥｐＣＡＭ、ＭＵＣ１、ＰＲＡＭＥ、サバイビン、ＢＲＣＡ１、ＢＲＣＡ２、ＣＤＫ４、ＣＭＬ６６、ＭＡＲＴ－２、ｐ５３、Ｒａｓ、β－カテニン、ＴＧＦ－βＲＩＩ、ＨＰＶ Ｅ６、又はＨＰＶ Ｅ７に由来するペプチドを含むＭＨＣ／ペプチド複合体からなる群から選択される、請求項１９に記載の医薬。 Antigens expressed by cancer are CD19, CD20, CD22, CD30, CD33, CD38, CD52, CD56, CD70, CD74, CD79b, CD123, CD138, CS1 / SLAMF7, Trop-2, 5T4, EphA4, BCMA, mutin. 1, Mutin 16, PTK7, STEP1, Endoserin B-type receptor, Mesoterin, EGFRvIII, ENPP3, SLC44A4, GNMB, Nectin 4, NaPi2b, LIV-1A, Guanylate cyclase C, DLL3, EGFR, HER2, VEGF, VEGFR, Integrin αVβ3, integrin α5β1, MET, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, tenacin , Lee, EpCAM, CEA, gpA33, PSMA, TAG72, mutin, CAIX, EPHA3, folic acid receptor α, GD2, GD3 ESO-1 / LAGE, SSX-2, MAGE family protein, MAGE-A3, gp100 / pmel17, Melan-A / MART-1, gp75 / TRP1, tyrosinase, TRP2, CEA, PSA, TAG-72, immature laminin receptor Body, MOK / RAGE-1, WT-1, SAP-1, BING-4, EpCAM, MUC1, PRAME, Survival, BRCA1, BRCA2, CDK4, CML66, MART-2, p53, Ras, β-catenin, TGF- The pharmaceutical according to claim 19, which is selected from the group consisting of an MHC / peptide complex containing a peptide derived from βRII, HPV E6, or HPV E7. 免疫療法剤の有効量が個体にさらに投与される、請求項１７、１９～２０のいずれか１項に記載の医薬。 The medicine according to any one of claims 17 and 19 to 20, wherein an effective amount of an immunotherapeutic agent is further administered to an individual. 免疫療法剤が第２の抗体を含む、請求項２１に記載の医薬。 The medicine according to claim 21, wherein the immunotherapeutic agent comprises a second antibody. 第２の抗体が、ＢＤＣＡ２、ＢＤＣＡ４、ＩＬＴ７、ＬＩＬＲＢ１、ＬＩＬＲＢ２、ＬＩＬＲＢ３、ＬＩＬＲＢ４、ＬＩＬＲＢ５、Ｓｉｇｌｅｃ－３、Ｓｉｇｌｅｃ－７、Ｓｉｇｌｅｃ－９、Ｓｉｇｌｅｃ－１５、ＦＧＬ－１、ＣＤ２００、ＣＤ２００Ｒ、ＣＳＦ－１Ｒ、ＣＤ４０、ＣＤ４０Ｌ、ＣＤ１６３、ＣＤ２０６、ＤＥＣ２０５、ＣＤ４７、ＣＤ１２３、アルギナーゼ、ＩＤＯ、ＴＤＯ、ＡｈＲ、ＥＰ２、ＣＯＸ－２、ＣＣＲ２、ＣＣＲ－７、ＣＸＣＲ１、ＣＸ３ＣＲ１、ＣＸＣＲ２、ＣＸＣＲ３、ＣＸＣＲ４、ＣＸＣＲ７、ＴＧＦ－β ＲＩ、ＴＧＦ－β ＲＩＩ、ｃ－Ｋｉｔ、ＣＤ２４４、Ｌ－セレクチン／ＣＤ６２Ｌ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤ６８、４１ＢＢ、ＣＴＬＡ４、ＰＤ１、ＰＤ－Ｌ１、ＰＤ－Ｌ２、ＴＩＭ－３、ＢＴＬＡ、ＶＩＳＴＡ、ＬＡＧ－３、ＣＤ２８、ＯＸ４０、ＧＩＴＲ、ＣＤ１３７、ＣＤ２７、ＨＶＥＭ、ＣＣＲ４、ＣＤ２５、ＣＤ１０３、ＫＩｒｇ１、Ｎｒｐ１、ＣＤ２７８、Ｇｐｒ８３、ＴＩＧＩＴ、ＣＤ１５４、ＣＤ１６０、ＴＮＦＲ２、ＰＶＲＩＧ、ＤＮＡＭ、及びＩＣＯＳからなる群から選択される抗原に結合する、請求項２２に記載の医薬。 The second antibody is BDCA2, BDCA4, ILT7, LILRB1, LILRB2, LILRB3, LILRB4, LILRB5, Sigma-3, Sigma-7, Sigma-9, Sigma-15, FGL-1, CD200, CD200R, CSF-1R, CD40, CD40L, CD163, CD206, DEC205, CD47, CD123, antigenase, IDO, TDO, AhR, EP2, COX-2, CCR2, CCR-7, CXCR1, CX3CR1, CXCR2, CXCR3, CXCR4, CXCR7, TGF-β RI , TGF-β RII, c-Kit, CD244, L-selectin / CD62L, CD11b, CD11c, CD68, 41BB, CTLA4, PD1, PD-L1, PD-L2, TIM-3, BTLA, VISTA, LAG-3, Binds to an antigen selected from the group consisting of CD28, OX40, GITR, CD137, CD27, HVEM, CCR4, CD25, CD103, KIrg1, Nrp1, CD278, Gpr83, TIGIT, CD154, CD160, TNFR2, PVRIG, DNAM, and ICOS. 22. The pharmaceutical agent according to claim 22. 第２の抗体がＰＤ－１に結合する、請求項２３に記載の医薬。 The medicine according to claim 23, wherein the second antibody binds to PD-1. 第２の抗体がＰＤ－Ｌ１に結合する、請求項２３に記載の医薬。 The medicine according to claim 23, wherein the second antibody binds to PD-L1. 免疫療法剤が、ワクチン、腫瘍溶解性ウイルス、養子細胞療法、サイトカイン、又は小分子剤を含む、請求項２１に記載の医薬。 21. The pharmaceutical agent of claim 21, wherein the immunotherapeutic agent comprises a vaccine, an oncolytic virus, an adoptive cell therapy, a cytokine, or a small molecule agent. ナチュラルキラー（ＮＫ）細胞により発現される抗原に結合する第２の抗体の有効量が個体にさらに投与される、請求項１７、１９～２６のいずれか１項に記載の医薬。 The pharmaceutical according to any one of claims 17 and 19 to 26, wherein an effective amount of a second antibody that binds to an antigen expressed by a natural killer (NK) cell is further administered to an individual. ＮＫ細胞により発現される抗原が、ＮＫＲ－Ｐ１Ａ、ＣＤ９４、ＫＬＲＧ１、ＫＩＲ２ＤＬ５Ａ、ＫＩＲ２ＤＬ５Ｂ、ＫＩＲ２ＤＬ１、ＫＩＲ２ＤＬ２、ＫＩＲ２ＤＬ３、ＫＩＲ２ＤＳ２、ＫＩＲ２ＤＳ３、ＫＩＲ２ＤＳ４、ＫＩＲ２ＤＳ５、ＫＩＲ３ＤＳ１、ＫＩＲ２ＤＳ１、ＣＤ９４、ＮＫＧ２Ｄ、ＣＤ１６０、ＣＤ１６、ＮＫｐ４６、ＮＫｐ３０、ＮＫｐ４４、ＤＮＡＭ１、ＣＲＴＡＭ、ＣＤ２７、ＮＴＢ－Ａ、ＰＳＧＬ１、ＣＤ９６、ＣＤ１００、ＮＫｐ８０、ＳＬＡＭＦ７、及びＣＤ２４４からなる群から選択される、請求項２７に記載の医薬。 Antigens expressed by NK cells are NKR-P1A, CD94, KLRG1, KIR2DL5A, KIR2DL5B, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1, KIR2DS1 27, the pharmaceutical according to claim 27, which is selected from the group consisting of NKp44, DNAM1, CRTAM, CD27, NTB-A, PSGL1, CD96, CD100, NKp80, SLAMF7, and CD244. 化学療法剤又は小分子抗がん剤の有効量が個体にさらに投与される、請求項１７、１９～２８のいずれか１項に記載の医薬。 The pharmaceutical according to any one of claims 17 and 19 to 28, wherein an effective amount of a chemotherapeutic agent or a small molecule anticancer agent is further administered to an individual. 標的化小分子阻害剤の有効量が個体にさらに投与される、請求項１７、１９～２９のいずれか１項に記載の医薬。 The pharmaceutical according to any one of claims 17 and 19-29, wherein an effective amount of the targeted small molecule inhibitor is further administered to the individual. 標的化小分子阻害剤が、ＶＥＧＦＲ及び／又はＰＤＧＦＲ阻害剤、ＥＧＦＲ阻害剤、ＡＬＫ阻害剤、ＣＤＫ４／６阻害剤、ＰＡＲＰ阻害剤、ｍＴＯＲ阻害剤、ＫＲＡＳ阻害剤、ＴＲＫ阻害剤、ＢＣＬ２阻害剤、ＩＤＨ阻害剤、ＰＩ３Ｋ阻害剤、ＤＮＡ損傷応答（ＤＤＲ）阻害剤、又は低メチル化剤である、請求項３０に記載の医薬。 Targeted small molecule inhibitors include VEGFR and / or PDGFR inhibitors, EGFR inhibitors, ALK inhibitors, CDK4 / 6 inhibitors, PARP inhibitors, mTOR inhibitors, KRAS inhibitors, TRK inhibitors, BCL2 inhibitors, 30. The pharmaceutical according to claim 30, which is an IDH inhibitor, a PI3K inhibitor, a DNA damage response (DDR) inhibitor, or a hypomethylating agent. 請求項１～１１のいずれか１項に記載の抗体の有効量を含む、個体における自己免疫疾患又は炎症性疾患の進行を治療又は遅延するための医薬。 A pharmaceutical agent comprising an effective amount of the antibody according to any one of claims 1 to 11 for treating or delaying the progression of an autoimmune disease or an inflammatory disease in an individual. 個体の自己免疫疾患又は炎症性疾患を治療する又は個体の自己免疫疾患又は炎症性疾患の進行を遅らせるための医薬を製造するための、請求項１～１１のいずれか１項に記載の抗体の使用。 The antibody according to any one of claims 1 to 11 for producing a drug for treating an individual's autoimmune disease or inflammatory disease or delaying the progression of the individual's autoimmune disease or inflammatory disease. use. 自己免疫疾患又は炎症性疾患が、多発性硬化症、関節リウマチ、脊椎関節症、全身性エリテマトーデス、抗体媒介性の炎症性疾患又は自己免疫疾患、移植片対宿主病、敗血症、糖尿病、乾癬、乾癬性関節炎、アテローム性動脈硬化症、シェーグレン症候群、全身性進行性硬化症、強皮症、急性冠症候群、虚血再灌流、クローン病、潰瘍性大腸炎、子宮内膜症、糸球体腎炎、ＩｇＡ腎症、多発性嚢胞腎疾患、重症筋無力症、特発性肺線維症、肺線維症、肝硬変、心房線維症、心筋線維症、骨髄線維症、後腹膜線維症、喘息、アトピー性皮膚炎、急性呼吸促迫症候群（ＡＲＤＳ）、血管炎、及び自己免疫性炎症性筋炎からなる群から選択される、請求項３３に記載の医薬。 Autoimmune or inflammatory diseases include multiple sclerosis, rheumatoid arthritis, spondyloarthropathies, systemic erythematosus, antibody-mediated inflammatory or autoimmune diseases, transplant-to-host disease, sepsis, diabetes, psoriasis, psoriasis Arthritis, atherosclerosis, Schegren's syndrome, systemic progressive sclerosis, scleroderma, acute coronary syndrome, ischemia-reperfusion, Crohn's disease, ulcerative colitis, endometriosis, glomerular nephritis, IgA Nephropathy, multiple cystic kidney disease, severe myasthenia, idiopathic pulmonary fibrosis, pulmonary fibrosis, liver cirrhosis, atrial fibrosis, myocardial fibrosis, myeloid fibrosis, retroperitoneal fibrosis, asthma, atopic dermatitis, 33. The pharmaceutical agent according to claim 33, which is selected from the group consisting of acute respiratory urgency syndrome (ARDS), vasculitis, and autoimmune inflammatory myitis. ヒトＳＩＲＰ－αポリペプチドの細胞外ドメインに結合する単離された抗体であって、
（ａ）配列番号２６のアミノ酸配列を含む重鎖可変（ＶＨ）ドメインを含む重鎖；及び
（ｂ）式ＳＹＥＬＴＱＰＰＳＶＳＶＳＰＧＱＴＡＲＩＴＣＳＧＧＳＹＳＳＹＹＹＡＷＹＱＱＫＰＧＱＡＰＶＴＬＩＹＳＤＤＫＲＰＳＮＩＰＥＲＦＳＧＳＳＳＧＴＴＶＴＬＴＩＳＧＶＱＡＥＤＥＡＤＹＹＣＧＧＹＤＱＳＳＹＴＮＰＦＧＸ１ＧＴＸ２Ｘ３ＴＶＬ（配列番号７１）に従うアミノ酸配列を含む軽鎖可変（ＶＬ）ドメインを含む軽鎖を含み、ここで、Ｘ１は、Ｇ又はＴであり；Ｘ２は、Ｋ、Ｑ、又はＲであり；Ｘ３は、Ｌ又はＶであり、ＶＬドメインは、配列番号２５の配列を含まない、抗体。 An isolated antibody that binds to the extracellular domain of a human SIRP-α polypeptide.
(A) Heavy chain comprising a heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO: 26; and ( b) formula SYELTQPPSVSVSVGQSRGQSGGSYSSYYAWYQQKPGQAPVTLIYSDDKRPSNIPERFSGSSSGSTTVTLTISGVQAEDEDY ) Containing a light chain comprising a domain, where X 1 is G or T; X 2 is K, Q, or R; X 3 is L or V and the VL domain is a sequence. An antibody that does not contain the sequence number 25. ＶＬドメインが、配列番号３９～４１からなる群から選択されるアミノ酸配列を含む、請求項３５に記載の抗体。 35. The antibody of claim 35, wherein the VL domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 39-41. 軽鎖が、式ＧＱＰＫＡＮＰＴＶＴＬＦＰＰＳＳＥＥＬＱＡＮＫＡＴＬＶＣＬＩＳＤＦＹＰＧＡＶＴＶＡＷＫＡＤＧＳＰＶＫＡＧＶＥＴＴＫＰＳＫＱＳＸ４Ｘ５ＫＹＡＡＳＳＹＬＳＬＴＰＥＱＷＫＳＨＲＳＹＳＣＱＶＴＨＥＧＳＴＶＥＫＴＶＡＰＴＥＣＳ（配列番号７２）に従うアミノ酸配列を含む軽鎖定常（ＣＬ）ドメイン配列をさらに含み、ここで、Ｘ４Ｘ５が、ＮＤ、ＤＮ、ＤＳ、又はＳＤである、請求項３５又は３６に記載の抗体。 The light chain contains an amino acid according to the formula GQPKANPTVTPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSX 4 X 5 KYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 72). The antibody according to claim 35 or 36. 軽鎖が、配列番号４３～４６からなる群から選択されるアミノ酸配列を含む軽鎖定常（ＣＬ）ドメイン配列をさらに含む、請求項３５又は３６に記載の抗体。 The antibody of claim 35 or 36, wherein the light chain further comprises a light chain constant (CL) domain sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-46. 軽鎖が、κ軽鎖定常（ＣＬ）ドメインをさらに含む、請求項３５又は３６に記載の抗体。 The antibody according to claim 35 or 36, wherein the light chain further comprises a kappa light chain constant (CL) domain. 軽鎖が、配列番号３６のアミノ酸配列を含む、請求項３９に記載の抗体。 39. The antibody of claim 39, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 36. 軽鎖が、λ軽鎖定常（ＣＬ）ドメインをさらに含む、請求項３５又は３６に記載の抗体。 The antibody according to claim 35 or 36, wherein the light chain further comprises a λ light chain constant (CL) domain. 軽鎖が、配列番号３７又は配列番号３８のアミノ酸配列を含む、請求項４１に記載の抗体。 41. The antibody of claim 41, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 37 or SEQ ID NO: 38. 軽鎖が、配列番号４８～５７からなる群から選択されるアミノ酸配列を含む、請求項３５に記載の抗体。 35. The antibody of claim 35, wherein the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 48-57. ｓｃＦｖ－Ｆｃ、単一ドメイン抗体、一本鎖重鎖抗体、又は一本鎖軽鎖抗体である、請求項３５～４３のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 43, which is a scFv-Fc, a single domain antibody, a single chain heavy chain antibody, or a single chain light chain antibody. モノクローナル抗体である、請求項３５～４３のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 43, which is a monoclonal antibody. 重鎖が、Ｆｃ領域を含む重鎖定常ドメインを含む、請求項３５～４３のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 43, wherein the heavy chain comprises a heavy chain constant domain including an Fc region. Ｆｃ領域が、ＩｇＧ１ Ｆｃ領域、ＩｇＧ２ Ｆｃ領域、及びＩｇＧ４ Ｆｃ領域からなる群から選択されるヒトＦｃ領域である、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the Fc region is a human Fc region selected from the group consisting of an IgG1 Fc region, an IgG2 Fc region, and an IgG4 Fc region. Ｆｃ領域が、ヒトＩｇＧ１ Ｆｃ領域である、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the Fc region is a human IgG1 Fc region. Ｆｃ領域が、ＥＵに従うアミノ酸位置ナンバリングである、Ｌ２３４Ａ、Ｌ２３５Ａ、及びＧ２３７Ａ置換を含むヒトＩｇＧ１ Ｆｃ領域である、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the Fc region is a human IgG1 Fc region comprising L234A, L235A, and G237A substitutions, which is an amino acid position numbering according to the EU. Ｆｃ領域が、ＥＵに従うアミノ酸位置ナンバリングである、Ｎ２９７Ａ置換をさらに含む、請求項４９に記載の抗体。 49. The antibody of claim 49, further comprising an N297A substitution, wherein the Fc region is an amino acid position numbering according to the EU. Ｆｃ領域が、ヒトＩｇＧ２ Ｆｃ領域である、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the Fc region is a human IgG2 Fc region. Ｆｃ領域が、ＥＵに従うアミノ酸位置ナンバリングである、Ａ３３０Ｓ及びＰ３３１Ｓ置換を含むヒトＩｇＧ２ Ｆｃ領域である、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the Fc region is a human IgG2 Fc region comprising A330S and P331S substitutions, which is an amino acid position numbering according to the EU. Ｆｃ領域が、ＥＵに従うアミノ酸位置ナンバリングである、Ｎ２９７Ａ置換をさらに含む、請求項５１又は５２に記載の抗体。 The antibody according to claim 51 or 52, further comprising an N297A substitution, wherein the Fc region is an amino acid position numbering according to the EU. Ｆｃ領域が、ヒトＩｇＧ４ Ｆｃ領域であり、重鎖が、ＥＵに従うアミノ酸位置ナンバリングである、Ｓ２２８Ｐ置換を含む、請求項４６に記載の抗体。 46. The antibody of claim 46, comprising S228P substitution, wherein the Fc region is a human IgG4 Fc region and the heavy chain is an amino acid position numbering according to the EU. 重鎖定常ドメインが、配列番号３１～３５からなる群から選択されるアミノ酸配列を含む、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the heavy chain constant domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 31-35. 重鎖定常ドメインが、配列番号３３、３４、及び１３７からなる群から選択されるアミノ酸配列を含む、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the heavy chain constant domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 33, 34, and 137. 重鎖定常ドメインが、配列番号１３２～１３９からなる群から選択されるアミノ酸配列を含む、請求項４６に記載の抗体。 46. The antibody of claim 46, wherein the heavy chain constant domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 132-139. 重鎖が、配列番号５８～６２からなる群から選択されるアミノ酸配列を含む、請求項３５に記載の抗体。 35. The antibody of claim 35, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 58-62. 重鎖が、配列番号６０、６１、及び１２９からなる群から選択されるアミノ酸配列を含む、請求項３５に記載の抗体。 35. The antibody of claim 35, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 60, 61, and 129. （ａ）重鎖が、配列番号６２のアミノ酸配列を含み、軽鎖が、配列番号５２のアミノ酸配列を含む；
（ｂ）重鎖が、配列番号６２のアミノ酸配列を含み、軽鎖が、配列番号５３のアミノ酸配列を含む；
（ｃ）重鎖が、配列番号６２のアミノ酸配列を含み、軽鎖が、配列番号５４のアミノ酸配列を含む；
（ｄ）重鎖が、配列番号６２のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｅ）重鎖が、配列番号６２のアミノ酸配列を含み、軽鎖が、配列番号５６のアミノ酸配列を含む；又は
（ｆ）重鎖が、配列番号６２のアミノ酸配列を含み、軽鎖が、配列番号５７のアミノ酸配列を含む、
請求項３５に記載の抗体。 (A) The heavy chain comprises the amino acid sequence of SEQ ID NO: 62 and the light chain comprises the amino acid sequence of SEQ ID NO: 52;
(B) The heavy chain comprises the amino acid sequence of SEQ ID NO: 62 and the light chain comprises the amino acid sequence of SEQ ID NO: 53;
(C) The heavy chain comprises the amino acid sequence of SEQ ID NO: 62 and the light chain comprises the amino acid sequence of SEQ ID NO: 54;
(D) The heavy chain comprises the amino acid sequence of SEQ ID NO: 62 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(E) The heavy chain comprises the amino acid sequence of SEQ ID NO: 62 and the light chain comprises the amino acid sequence of SEQ ID NO: 56; or (f) the heavy chain comprises the amino acid sequence of SEQ ID NO: 62 and the light chain comprises. Containing the amino acid sequence of SEQ ID NO: 57,
The antibody according to claim 35. （ａ）重鎖が、配列番号５８のアミノ酸配列を含み、軽鎖が、配列番号５２のアミノ酸配列を含む；
（ｂ）重鎖が、配列番号５９のアミノ酸配列を含み、軽鎖が、配列番号５２のアミノ酸配列を含む
（ｃ）重鎖が、配列番号６０のアミノ酸配列を含み、軽鎖が、配列番号５２のアミノ酸配列を含む；
（ｄ）重鎖が、配列番号６１のアミノ酸配列を含み、軽鎖が、配列番号５２のアミノ酸配列を含む；
（ｅ）重鎖が、配列番号５８のアミノ酸配列を含み、軽鎖が、配列番号５３のアミノ酸配列を含む；
（ｆ）重鎖が、配列番号５９のアミノ酸配列を含み、軽鎖が、配列番号５３のアミノ酸配列を含む；
（ｇ）重鎖が、配列番号６０のアミノ酸配列を含み、軽鎖が、配列番号５３のアミノ酸配列を含む；
（ｈ）重鎖が、配列番号６１のアミノ酸配列を含み、軽鎖が、配列番号５３のアミノ酸配列を含む；
（ｉ）重鎖が、配列番号５８のアミノ酸配列を含み、軽鎖が、配列番号５４のアミノ酸配列を含む；
（ｊ）重鎖が、配列番号５９のアミノ酸配列を含み、軽鎖が、配列番号５４のアミノ酸配列を含む；
（ｋ）重鎖が、配列番号６０のアミノ酸配列を含み、軽鎖が、配列番号５４のアミノ酸配列を含む；
（ｌ）重鎖が、配列番号６１のアミノ酸配列を含み、軽鎖が、配列番号５４のアミノ酸配列を含む；
（ｍ）重鎖が、配列番号５８のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｎ）重鎖が、配列番号５９のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｏ）重鎖が、配列番号６０のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｐ）重鎖が、配列番号６１のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｑ）重鎖が、配列番号５８のアミノ酸配列を含み、軽鎖が、配列番号５６のアミノ酸配列を含む；
（ｒ）重鎖が、配列番号５９のアミノ酸配列を含み、軽鎖が、配列番号５６のアミノ酸配列を含む；
（ｓ）重鎖が、配列番号６０のアミノ酸配列を含み、軽鎖が、配列番号５６のアミノ酸配列を含む；
（ｔ）重鎖が、配列番号６１のアミノ酸配列を含み、軽鎖が、配列番号５６のアミノ酸配列を含む；
（ｕ）重鎖が、配列番号５８のアミノ酸配列を含み、軽鎖が、配列番号５７のアミノ酸配列を含む；
（ｖ）重鎖が、配列番号５９のアミノ酸配列を含み、軽鎖が、配列番号５７のアミノ酸配列を含む；
（ｗ）重鎖が、配列番号６０のアミノ酸配列を含み、軽鎖が、配列番号５７のアミノ酸配列を含む；又は
（ｘ）重鎖が、配列番号６１のアミノ酸配列を含み、軽鎖が、配列番号５７のアミノ酸配列を含む、
請求項３５に記載の抗体。 (A) The heavy chain comprises the amino acid sequence of SEQ ID NO: 58 and the light chain comprises the amino acid sequence of SEQ ID NO: 52;
(B) The heavy chain comprises the amino acid sequence of SEQ ID NO: 59 and the light chain comprises the amino acid sequence of SEQ ID NO: 52. (c) The heavy chain comprises the amino acid sequence of SEQ ID NO: 60 and the light chain comprises the amino acid sequence of SEQ ID NO: 60. Contains 52 amino acid sequences;
(D) The heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the light chain comprises the amino acid sequence of SEQ ID NO: 52;
(E) The heavy chain comprises the amino acid sequence of SEQ ID NO: 58 and the light chain comprises the amino acid sequence of SEQ ID NO: 53;
(F) The heavy chain comprises the amino acid sequence of SEQ ID NO: 59 and the light chain comprises the amino acid sequence of SEQ ID NO: 53;
(G) The heavy chain comprises the amino acid sequence of SEQ ID NO: 60 and the light chain comprises the amino acid sequence of SEQ ID NO: 53;
(H) The heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the light chain comprises the amino acid sequence of SEQ ID NO: 53;
(I) The heavy chain comprises the amino acid sequence of SEQ ID NO: 58 and the light chain comprises the amino acid sequence of SEQ ID NO: 54;
(J) The heavy chain comprises the amino acid sequence of SEQ ID NO: 59 and the light chain comprises the amino acid sequence of SEQ ID NO: 54;
(K) The heavy chain comprises the amino acid sequence of SEQ ID NO: 60 and the light chain comprises the amino acid sequence of SEQ ID NO: 54;
(L) The heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the light chain comprises the amino acid sequence of SEQ ID NO: 54;
(M) The heavy chain comprises the amino acid sequence of SEQ ID NO: 58 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(N) The heavy chain comprises the amino acid sequence of SEQ ID NO: 59 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(O) The heavy chain comprises the amino acid sequence of SEQ ID NO: 60 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(P) The heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(Q) The heavy chain comprises the amino acid sequence of SEQ ID NO: 58 and the light chain comprises the amino acid sequence of SEQ ID NO: 56;
(R) The heavy chain comprises the amino acid sequence of SEQ ID NO: 59 and the light chain comprises the amino acid sequence of SEQ ID NO: 56;
(S) The heavy chain comprises the amino acid sequence of SEQ ID NO: 60 and the light chain comprises the amino acid sequence of SEQ ID NO: 56;
(T) The heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the light chain comprises the amino acid sequence of SEQ ID NO: 56;
(U) The heavy chain comprises the amino acid sequence of SEQ ID NO: 58 and the light chain comprises the amino acid sequence of SEQ ID NO: 57;
(V) The heavy chain comprises the amino acid sequence of SEQ ID NO: 59 and the light chain comprises the amino acid sequence of SEQ ID NO: 57;
(W) The heavy chain comprises the amino acid sequence of SEQ ID NO: 60 and the light chain comprises the amino acid sequence of SEQ ID NO: 57; or (x) the heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the light chain comprises. Containing the amino acid sequence of SEQ ID NO: 57,
The antibody according to claim 35. （ａ）重鎖が、配列番号６０のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｂ）重鎖が、配列番号６１のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｃ）重鎖が、配列番号１２９のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む；
（ｄ）重鎖が、配列番号１２４のアミノ酸配列を含み、軽鎖が、配列番号５２のアミノ酸配列を含む；又は
（ｅ）重鎖が、配列番号１２４のアミノ酸配列を含み、軽鎖が、配列番号５５のアミノ酸配列を含む、
請求項３５に記載の抗体。 (A) The heavy chain comprises the amino acid sequence of SEQ ID NO: 60 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(B) The heavy chain comprises the amino acid sequence of SEQ ID NO: 61 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(C) The heavy chain comprises the amino acid sequence of SEQ ID NO: 129 and the light chain comprises the amino acid sequence of SEQ ID NO: 55;
(D) The heavy chain comprises the amino acid sequence of SEQ ID NO: 124 and the light chain comprises the amino acid sequence of SEQ ID NO: 52; or (e) the heavy chain comprises the amino acid sequence of SEQ ID NO: 124 and the light chain comprises. Containing the amino acid sequence of SEQ ID NO: 55,
The antibody according to claim 35. ヒトＳＩＲＰ－αポリペプチドを発現するマクロファージによるファゴサイトーシスを亢進する、請求項３５～６２のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 62, which enhances phagocytosis by macrophages expressing a human SIRP-α polypeptide. ヒトＳＩＲＰ－αポリペプチドを発現する樹状細胞の活性化を亢進する、請求項３５～６３のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 63, which enhances the activation of dendritic cells expressing a human SIRP-α polypeptide. ＣＤ４７を発現する腫瘍のインビボ成長を阻害する、請求項３５～６４のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 64, which inhibits the in vivo growth of a tumor expressing CD47. 薬剤にコンジュゲートされる、請求項３５～６５のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 65, which is conjugated to a drug. 二重特異性抗体である、請求項３５～６５のいずれか１項に記載の抗体。 The antibody according to any one of claims 35 to 65, which is a bispecific antibody. ヒトＳＩＲＰ－αポリペプチドの細胞外ドメインに結合する第１の抗原結合ドメインと、がん細胞により発現される抗原に結合する第２の抗原結合ドメインとを含む、請求項６７に記載の抗体。 22. The antibody of claim 67, comprising a first antigen-binding domain that binds to the extracellular domain of a human SIRP-α polypeptide and a second antigen-binding domain that binds to an antigen expressed by cancer cells. がん細胞により発現される抗原が、ＣＤ１９、ＣＤ２０、ＣＤ２２、ＣＤ３０、ＣＤ３３、ＣＤ３８、ＣＤ５２、ＣＤ５６、ＣＤ７０、ＣＤ７４、ＣＤ７９ｂ、ＣＤ１２３、ＣＤ１３８、ＣＳ１／ＳＬＡＭＦ７、Ｔｒｏｐ－２、５Ｔ４、ＥｐｈＡ４、ＢＣＭＡ、ムチン１、ムチン１６、ＰＤ－Ｌ１、ＰＴＫ７、ＳＴＥＡＰ１、エンドセリンＢ型受容体、メソテリン、ＥＧＦＲｖＩＩＩ、ＥＮＰＰ３、ＳＬＣ４４Ａ４、ＧＮＭＢ、ネクチン４、ＮａＰｉ２ｂ、ＬＩＶ－１Ａ、グアニル酸シクラーゼＣ、ＤＬＬ３、ＥＧＦＲ、ＨＥＲ２、ＶＥＧＦ、ＶＥＧＦＲ、インテグリンαＶβ３、インテグリンα５β１、ＭＥＴ、ＩＧＦ１Ｒ、ＴＲＡＩＬＲ１、ＴＲＡＩＬＲ２、ＲＡＮＫＬ、ＦＡＰ、テネイシン、Ｌｅｙ、ＥｐＣＡＭ、ＣＥＡ、ｇｐＡ３３、ＰＳＭＡ、ＴＡＧ７２、ムチン、ＣＡＩＸ、ＥＰＨＡ３、葉酸受容体α、ＧＤ２、ＧＤ３、及びＮＹ－ＥＳＯ－１／ＬＡＧＥ、ＳＳＸ－２、ＭＡＧＥファミリータンパク質、ＭＡＧＥ－Ａ３、ｇｐ１００／ｐｍｅｌ１７、Ｍｅｌａｎ－Ａ／ＭＡＲＴ－１、ｇｐ７５／ＴＲＰ１、チロシナーゼ、ＴＲＰ２、ＣＥＡ、ＰＳＡ、ＴＡＧ－７２、未成熟ラミニン受容体、ＭＯＫ／ＲＡＧＥ－１、ＷＴ－１、ＳＡＰ－１、ＢＩＮＧ－４、ＥｐＣＡＭ、ＭＵＣ１、ＰＲＡＭＥ、サバイビン、ＢＲＣＡ１、ＢＲＣＡ２、ＣＤＫ４、ＣＭＬ６６、ＭＡＲＴ－２、ｐ５３、Ｒａｓ、β－カテニン、ＴＧＦ－βＲＩＩ、ＨＰＶ Ｅ６又はＨＰＶ Ｅ７に由来するペプチドを含むＭＨＣ／ペプチド複合体からなる群から選択される、請求項６８に記載の抗体。 Antigens expressed by cancer cells are CD19, CD20, CD22, CD30, CD33, CD38, CD52, CD56, CD70, CD74, CD79b, CD123, CD138, CS1 / SLAMF7, Trop-2, 5T4, EphA4, BCMA, Mutin 1, Mutin 16, PD-L1, PTK7, STEP1, Endoserin B-type receptor, Mesoterin, EGFRvIII, ENPP3, SLC44A4, GNMB, Nectin4, NaPi2b, LIV-1A, Guanylic acid cyclase C, DLL3, EGFR, HER2, VEGF, VEGFR, integrin αVβ3, integrin α5β1, MET, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, tenacin , Lee, EpCAM, CEA, gpA33, PSMA, TAG72, mutin, CAIX, EPHA3 GD3 and NY-ESO-1 / LAGE, SSX-2, MAGE family protein, MAGE-A3, gp100 / pmel17, Melan-A / MART-1, gp75 / TRP1, tyrosinase, TRP2, CEA, PSA, TAG-72. , Immature Laminine Receptor, MOK / RAGE-1, WT-1, SAP-1, BING-4, EpCAM, MUC1, PRAME, Survival, BRCA1, BRCA2, CDK4, CML66, MART-2, p53, Ras, β -The antibody of claim 68, selected from the group consisting of an MHC / peptide complex comprising a peptide derived from -catenin, TGF-βRII, HPV E6 or HPV E7. ヒトＳＩＲＰ－αポリペプチドの細胞外ドメインに結合する第１の抗原結合ドメインと、免疫細胞によって発現される抗原に結合する第２の抗原結合ドメインとを含む、請求項６７に記載の抗体。 22. The antibody of claim 67, comprising a first antigen-binding domain that binds to the extracellular domain of a human SIRP-α polypeptide and a second antigen-binding domain that binds to an antigen expressed by immune cells. 免疫細胞によって発現される抗原が、ＢＤＣＡ２、ＢＤＣＡ４、ＩＬＴ７、ＬＩＬＲＢ１、ＬＩＬＲＢ２、ＬＩＬＲＢ３、ＬＩＬＲＢ４、ＬＩＬＲＢ５、Ｓｉｇｌｅｃ－３、Ｓｉｇｌｅｃ－７、Ｓｉｇｌｅｃ－９、Ｓｉｇｌｅｃ－１５、ＦＧＬ－１、ＣＤ２００、ＣＤ２００Ｒ、ＣＳＦ－１Ｒ、ＣＤ４０、ＣＤ４０Ｌ、ＣＤ１６３、ＣＤ２０６、ＤＥＣ２０５、ＣＤ４７、ＣＤ１２３、アルギナーゼ、ＩＤＯ、ＴＤＯ、ＡｈＲ、ＥＰ２、ＣＯＸ－２、ＣＣＲ２、ＣＣＲ－７、ＣＸＣＲ１、ＣＸ３ＣＲ１、ＣＸＣＲ２、ＣＸＣＲ３、ＣＸＣＲ４、ＣＸＣＲ７、ＴＧＦ－β ＲＩ、ＴＧＦ－β ＲＩＩ、ｃ－Ｋｉｔ、ＣＤ２４４、Ｌ－セレクチン／ＣＤ６２Ｌ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤ６８、４１ＢＢ、ＣＴＬＡ４、ＰＤ１、ＰＤ－Ｌ１、ＰＤ－Ｌ２、ＴＩＭ－３、ＢＴＬＡ、ＶＩＳＴＡ、ＬＡＧ－３、ＣＤ２８、ＯＸ４０、ＧＩＴＲ、ＣＤ１３７、ＣＤ２７、ＨＶＥＭ、ＣＣＲ４、ＣＤ２５、ＣＤ１０３、ＫＩｒｇ１、Ｎｒｐ１、ＣＤ２７８、Ｇｐｒ８３、ＴＩＧＩＴ、ＣＤ１５４、ＣＤ１６０、ＴＮＦＲ２、ＰＶＲＩＧ、ＤＮＡＭ、及びＩＣＯＳからなる群から選択される、請求項７０に記載の抗体。 The antigens expressed by immune cells are BDCA2, BDCA4, ILT7, LILRB1, LILRB2, LILRB3, LILRB4, LILRB5, Sigma-3, Sigma-7, Sigma-9, Sigma-15, FGL-1, CD200, CD200R, CSF. -1R, CD40, CD40L, CD163, CD206, DEC205, CD47, CD123, arginase, IDO, TDO, AhR, EP2, COX-2, CCR2, CCR-7, CXCR1, CX3CR1, CXCR2, CXCR3, CXCR4, CXCR7, TGF -Β RI, TGF-β RII, c-Kit, CD244, L-selectin / CD62L, CD11b, CD11c, CD68, 41BB, CTLA4, PD1, PD-L1, PD-L2, TIM-3, BTLA, VISTA, LAG -3, CD28, OX40, GITR, CD137, CD27, HVEM, CCR4, CD25, CD103, KIrg1, Nrp1, CD278, Gpr83, TIGIT, CD154, CD160, TNFR2, PVRIG, DNAM, and ICOS. , The antibody according to claim 70. ヒトＳＩＲＰ－αポリペプチドの細胞外ドメインに結合する第１の抗原結合ドメインと、ナチュラルキラー（ＮＫ）細胞により発現される抗原に結合する第２の抗原結合ドメインとを含む、請求項６７に記載の抗体。 67. Antigen. ＮＫ細胞により発現される抗原が、ＮＫＲ－Ｐ１Ａ、ＣＤ９４、ＫＬＲＧ１、ＫＩＲ２ＤＬ５Ａ、ＫＩＲ２ＤＬ５Ｂ、ＫＩＲ２ＤＬ１、ＫＩＲ２ＤＬ２、ＫＩＲ２ＤＬ３、ＫＩＲ２ＤＳ２、ＫＩＲ２ＤＳ３、ＫＩＲ２ＤＳ４、ＫＩＲ２ＤＳ５、ＫＩＲ３ＤＳ１、ＫＩＲ２ＤＳ１、ＣＤ９４、ＮＫＧ２Ｄ、ＣＤ１６０、ＣＤ１６、ＮＫｐ４６、ＮＫｐ３０、ＮＫｐ４４、ＤＮＡＭ１、ＣＲＴＡＭ、ＣＤ２７、ＮＴＢ－Ａ、ＰＳＧＬ１、ＣＤ９６、ＣＤ１００、ＮＫｐ８０、ＳＬＡＭＦ７、及びＣＤ２４４からなる群から選択される、請求項７２に記載の抗体。 Antigens expressed by NK cells are NKR-P1A, CD94, KLRG1, KIR2DL5A, KIR2DL5B, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1, KIR2DS1 72. The antibody of claim 72, which is selected from the group consisting of NKp44, DNAM1, CRTAM, CD27, NTB-A, PSGL1, CD96, CD100, NKp80, SLAMF7, and CD244. 請求項３５～７３のいずれか１項に記載の抗体をコードする、ポリヌクレオチド。 A polynucleotide encoding the antibody according to any one of claims 35 to 73. 請求項７４に記載のポリヌクレオチドを含む、ベクター。 A vector comprising the polynucleotide according to claim 74. 請求項７４に記載のポリヌクレオチド又は請求項７５に記載のベクターを含む、宿主細胞。 A host cell comprising the polynucleotide according to claim 74 or the vector according to claim 75. 抗体が産生されるように、請求項７６に記載の宿主細胞を培養することを含む、抗体を産生する方法。 The method for producing an antibody, which comprises culturing the host cell according to claim 76 so that the antibody is produced. 宿主細胞から抗体を回収することをさらに含む、請求項７７に記載の方法。 17. The method of claim 77, further comprising recovering the antibody from the host cell. 請求項３５～７３のいずれか１項に記載の抗体の有効量を含む、個体のがんを治療する又は個体のがんの進行を遅らせるための医薬。 A pharmaceutical agent comprising an effective amount of the antibody according to any one of claims 35 to 73 for treating an individual's cancer or delaying the progression of the individual's cancer. 個体のがんを治療する又は個体のがんの進行を遅らせるための医薬を製造するための、請求項３５～７３のいずれか１項に記載の抗体の使用。 Use of the antibody according to any one of claims 35 to 73 for producing a drug for treating an individual's cancer or delaying the progression of the individual's cancer. がんによって発現される抗原に結合する第２の抗体の有効量を個体に投与することをさらに含む、請求項７９に記載の医薬。 39. The apparatus of claim 79, further comprising administering to an individual an effective amount of a second antibody that binds to an antigen expressed by cancer. がん細胞により発現される抗原が、ＣＤ１９、ＣＤ２０、ＣＤ２２、ＣＤ３０、ＣＤ３３、ＣＤ３８、ＣＤ５２、ＣＤ５６、ＣＤ７０、ＣＤ７４、ＣＤ７９ｂ、ＣＤ１２３、ＣＤ１３８、ＣＳ１／ＳＬＡＭＦ７、Ｔｒｏｐ－２、５Ｔ４、ＥｐｈＡ４、ＢＣＭＡ、ムチン１、ムチン１６、ＰＴＫ７、ＳＴＥＡＰ１、エンドセリンＢ型受容体、メソテリン、ＥＧＦＲｖＩＩＩ、ＥＮＰＰ３、ＳＬＣ４４Ａ４、ＧＮＭＢ、ネクチン４、ＮａＰｉ２ｂ、ＬＩＶ－１Ａ、グアニル酸シクラーゼＣ、ＤＬＬ３、ＥＧＦＲ、ＨＥＲ２、ＶＥＧＦ、ＶＥＧＦＲ、インテグリンαＶβ３、インテグリンα５β１、ＭＥＴ、ＩＧＦ１Ｒ、ＴＲＡＩＬＲ１、ＴＲＡＩＬＲ２、ＲＡＮＫＬ、ＦＡＰ、テネイシン、Ｌｅｙ、ＥｐＣＡＭ、ＣＥＡ、ｇｐＡ３３、ＰＳＭＡ、ＴＡＧ７２、ムチン、ＣＡＩＸ、ＥＰＨＡ３、葉酸受容体α、ＧＤ２、ＧＤ３、及びＮＹ－ＥＳＯ－１／ＬＡＧＥ、ＳＳＸ－２、ＭＡＧＥファミリータンパク質、ＭＡＧＥ－Ａ３、ｇｐ１００／ｐｍｅｌ１７、Ｍｅｌａｎ－Ａ／ＭＡＲＴ－１、ｇｐ７５／ＴＲＰ１、チロシナーゼ、ＴＲＰ２、ＣＥＡ、ＰＳＡ、ＴＡＧ－７２、未成熟ラミニン受容体、ＭＯＫ／ＲＡＧＥ－１、ＷＴ－１、ＳＡＰ－１、ＢＩＮＧ－４、ＥｐＣＡＭ、ＭＵＣ１、ＰＲＡＭＥ、サバイビン、ＢＲＣＡ１、ＢＲＣＡ２、ＣＤＫ４、ＣＭＬ６６、ＭＡＲＴ－２、ｐ５３、Ｒａｓ、β－カテニン、ＴＧＦ－βＲＩＩ、ＨＰＶ Ｅ６又はＨＰＶ Ｅ７に由来するペプチドを含むＭＨＣ／ペプチド複合体からなる群から選択される、請求項８１に記載の医薬。 Antigens expressed by cancer cells are CD19, CD20, CD22, CD30, CD33, CD38, CD52, CD56, CD70, CD74, CD79b, CD123, CD138, CS1 / SLAMF7, Trop-2, 5T4, EphA4, BCMA, Mutin 1, Mutin 16, PTK7, STEP1, Endoserin B-type receptor, Mesoterin, EGFRvIII, ENPP3, SLC44A4, GNMB, Nectin 4, NaPi2b, LIV-1A, Guanyl acid cyclase C, DLL3, EGFR, HER2, VEGF, VEGFR, Integrin αVβ3, Integrin α5β1, MET, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, Tenacein , Lee, EpCAM, CEA, gpA33, PSMA, TAG72, Mutin, CAIX, EPHA3, Folic acid receptor α, G2 -ESO-1 / LAGE, SSX-2, MAGE family protein, MAGE-A3, gp100 / pmel17, Melan-A / MART-1, gp75 / TRP1, tyrosinase, TRP2, CEA, PSA, TAG-72, immature laminin Receptors, MOK / RAGE-1, WT-1, SAP-1, BING-4, EpCAM, MUC1, PRAME, Survival, BRCA1, BRCA2, CDK4, CML66, MART-2, p53, Ras, β-catenin, TGF -The pharmaceutical according to claim 81, selected from the group consisting of MHC / peptide complexes comprising peptides derived from βRII, HPV E6 or HPV E7. 免疫療法剤の有効量が個体にさらに投与される、請求項７９、８１、８２のいずれか１項に記載の医薬。 The medicine according to any one of claims 79, 81, 82, wherein an effective amount of an immunotherapeutic agent is further administered to an individual. 免疫療法剤が、第２の抗体を含む、請求項８３に記載の医薬。 The medicine according to claim 83, wherein the immunotherapeutic agent comprises a second antibody. 第２の抗体が、ＢＤＣＡ２、ＢＤＣＡ４、ＩＬＴ７、ＬＩＬＲＢ１、ＬＩＬＲＢ２、ＬＩＬＲＢ３、ＬＩＬＲＢ４、ＬＩＬＲＢ５、Ｓｉｇｌｅｃ－３、Ｓｉｇｌｅｃ－７、Ｓｉｇｌｅｃ－９、Ｓｉｇｌｅｃ－１５、ＦＧＬ－１、ＣＤ２００、ＣＤ２００Ｒ、ＣＳＦ－１Ｒ、ＣＤ４０、ＣＤ４０Ｌ、ＣＤ１６３、ＣＤ２０６、ＤＥＣ２０５、ＣＤ４７、ＣＤ１２３、アルギナーゼ、ＩＤＯ、ＴＤＯ、ＡｈＲ、ＥＰ２、ＣＯＸ－２、ＣＣＲ２、ＣＣＲ－７、ＣＸＣＲ１、ＣＸ３ＣＲ１、ＣＸＣＲ２、ＣＸＣＲ３、ＣＸＣＲ４、ＣＸＣＲ７、ＴＧＦ－β ＲＩ、ＴＧＦ－β ＲＩＩ、ｃ－Ｋｉｔ、ＣＤ２４４、Ｌ－セレクチン／ＣＤ６２Ｌ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤ６８、４１ＢＢ、ＣＴＬＡ４、ＰＤ１、ＰＤ－Ｌ１、ＰＤ－Ｌ２、ＴＩＭ－３、ＢＴＬＡ、ＶＩＳＴＡ、ＬＡＧ－３、ＣＤ２８、ＯＸ４０、ＧＩＴＲ、ＣＤ１３７、ＣＤ２７、ＨＶＥＭ、ＣＣＲ４、ＣＤ２５、ＣＤ１０３、ＫＩｒｇ１、Ｎｒｐ１、ＣＤ２７８、Ｇｐｒ８３、ＴＩＧＩＴ、ＣＤ１５４、ＣＤ１６０、ＴＮＦＲ２、ＰＶＲＩＧ、ＤＮＡＭ、及びＩＣＯＳからなる群から選択される抗原に結合する、請求項８４に記載の医薬。 The second antibody is BDCA2, BDCA4, ILT7, LILRB1, LILRB2, LILRB3, LILRB4, LILRB5, Sigma-3, Sigma-7, Sigma-9, Sigma-15, FGL-1, CD200, CD200R, CSF-1R, CD40, CD40L, CD163, CD206, DEC205, CD47, CD123, antigenase, IDO, TDO, AhR, EP2, COX-2, CCR2, CCR-7, CXCR1, CX3CR1, CXCR2, CXCR3, CXCR4, CXCR7, TGF-β RI , TGF-β RII, c-Kit, CD244, L-selectin / CD62L, CD11b, CD11c, CD68, 41BB, CTLA4, PD1, PD-L1, PD-L2, TIM-3, BTLA, VISTA, LAG-3, Binds to an antigen selected from the group consisting of CD28, OX40, GITR, CD137, CD27, HVEM, CCR4, CD25, CD103, KIrg1, Nrp1, CD278, Gpr83, TIGIT, CD154, CD160, TNFR2, PVRIG, DNAM, and ICOS. The medicine according to claim 84. 第２の抗体が、ＰＤ－１に結合する、請求項８５に記載の医薬。 The medicine according to claim 85, wherein the second antibody binds to PD-1. 第２の抗体が、ＰＤ－Ｌ１に結合する、請求項８５に記載の医薬。 The medicine according to claim 85, wherein the second antibody binds to PD-L1. 免疫療法剤が、ワクチン、腫瘍溶解性ウイルス、養子細胞療法、サイトカイン、又は小分子剤を含む、請求８３に記載の医薬。 38. The pharmaceutical agent of claim 83, wherein the immunotherapeutic agent comprises a vaccine, an oncolytic virus, adoptive cell therapy, a cytokine, or a small molecule agent. ナチュラルキラー（ＮＫ）細胞により発現される抗原に結合する第２の抗体の有効量が個体にさらに投与される、請求項７９、８１～８８のいずれか１項に記載の方法。 The method of any one of claims 79, 81-88, wherein an effective amount of a second antibody that binds to an antigen expressed by a natural killer (NK) cell is further administered to the individual. ＮＫ細胞により発現される抗原が、ＮＫＲ－Ｐ１Ａ、ＣＤ９４、ＫＬＲＧ１、ＫＩＲ２ＤＬ５Ａ、ＫＩＲ２ＤＬ５Ｂ、ＫＩＲ２ＤＬ１、ＫＩＲ２ＤＬ２、ＫＩＲ２ＤＬ３、ＫＩＲ２ＤＳ２、ＫＩＲ２ＤＳ３、ＫＩＲ２ＤＳ４、ＫＩＲ２ＤＳ５、ＫＩＲ３ＤＳ１、ＫＩＲ２ＤＳ１、ＣＤ９４、ＮＫＧ２Ｄ、ＣＤ１６０、ＣＤ１６、ＮＫｐ４６、ＮＫｐ３０、ＮＫｐ４４、ＤＮＡＭ１、ＣＲＴＡＭ、ＣＤ２７、ＮＴＢ－Ａ、ＰＳＧＬ１、ＣＤ９６、ＣＤ１００、ＮＫｐ８０、ＳＬＡＭＦ７、及びＣＤ２４４からなる群から選択される、請求項８９に記載の医薬。 Antigens expressed by NK cells are NKR-P1A, CD94, KLRG1, KIR2DL5A, KIR2DL5B, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1, KIR2DS1 , NKp44, DNAM1, CRTAM, CD27, NTB-A, PSGL1, CD96, CD100, NKp80, SLAMF7, and CD244. 化学療法剤又は小分子抗がん剤の有効量が個体にさらに投与される、請求項７９、８１～９０のいずれか１項に記載の医薬。 The medicine according to any one of claims 79, 81 to 90, wherein an effective amount of a chemotherapeutic agent or a small molecule anticancer agent is further administered to an individual. 標的化小分子阻害剤の有効量が個体にさらに投与される、請求項７９、８１～９１のいずれか１項に記載の医薬。 The pharmaceutical according to any one of claims 79, 81-91, wherein an effective amount of the targeted small molecule inhibitor is further administered to the individual. 標的化小分子阻害剤が、ＶＥＧＦＲ及び／又はＰＤＧＦＲ阻害剤、ＥＧＦＲ阻害剤、ＡＬＫ阻害剤、ＣＤＫ４／６阻害剤、ＰＡＲＰ阻害剤、ｍＴＯＲ阻害剤、ＫＲＡＳ阻害剤、ＴＲＫ阻害剤、ＢＣＬ２阻害剤、ＩＤＨ阻害剤、ＰＩ３Ｋ阻害剤、ＤＮＡ損傷応答（ＤＤＲ）阻害剤、又は低メチル化剤である、請求項９２に記載の医薬。 Targeted small molecule inhibitors include VEGFR and / or PDGFR inhibitors, EGFR inhibitors, ALK inhibitors, CDK4 / 6 inhibitors, PARP inhibitors, mTOR inhibitors, KRAS inhibitors, TRK inhibitors, BCL2 inhibitors, The pharmaceutical according to claim 92, which is an IDH inhibitor, a PI3K inhibitor, a DNA damage response (DDR) inhibitor, or a hypomethylating agent. 請求項３５～７３のいずれか１項に記載の抗体の有効量を含む、個体の自己免疫疾患又は炎症性疾患を治療する又は個体の自己免疫疾患又は炎症性疾患の進行を遅らせるための医薬。 A pharmaceutical agent comprising an effective amount of the antibody according to any one of claims 35 to 73 for treating an individual's autoimmune disease or inflammatory disease or delaying the progression of the individual's autoimmune disease or inflammatory disease. 個体の自己免疫疾患又は炎症性疾患を治療する又は個体の自己免疫疾患又は炎症性疾患の進行を遅らせるための医薬を製造するための、請求項３５～７３のいずれか１項に記載の抗体の使用。 The antibody according to any one of claims 35 to 73 for producing a drug for treating an individual's autoimmune disease or inflammatory disease or delaying the progression of the individual's autoimmune disease or inflammatory disease. use. 自己免疫疾患又は炎症性疾患が、多発性硬化症、関節リウマチ、脊椎関節症、全身性エリテマトーデス、抗体媒介性の炎症性疾患又は自己免疫疾患、移植片対宿主病、敗血症、糖尿病、乾癬、乾癬性関節炎、アテローム性動脈硬化症、シェーグレン症候群、全身性進行性硬化症、強皮症、急性冠症候群、虚血再灌流、クローン病、潰瘍性大腸炎、子宮内膜症、糸球体腎炎、ＩｇＡ腎症、多発性嚢胞腎疾患、重症筋無力症、特発性肺線維症、肺線維症、肝硬変、心房線維症、心筋線維症、骨髄線維症、後腹膜線維症、喘息、アトピー性皮膚炎、急性呼吸促迫症候群（ＡＲＤＳ）、血管炎及び自己免疫性炎症性筋炎からなる群から選択される、請求項９５に記載の医薬。 Autoimmune or inflammatory diseases include multiple sclerosis, rheumatoid arthritis, spondyloarthropathies, systemic erythematosus, antibody-mediated inflammatory or autoimmune diseases, transplant-to-host disease, sepsis, diabetes, psoriasis, psoriasis Arthritis, atherosclerosis, Schegren's syndrome, systemic progressive sclerosis, scleroderma, acute coronary syndrome, ischemia-reperfusion, Crohn's disease, ulcerative colitis, endometriosis, glomerular nephritis, IgA Nephropathy, multiple cystic kidney disease, severe myasthenia, idiopathic pulmonary fibrosis, pulmonary fibrosis, liver cirrhosis, atrial fibrosis, myocardial fibrosis, myeloid fibrosis, retroperitoneal fibrosis, asthma, atopic dermatitis, The pharmaceutical according to claim 95, which is selected from the group consisting of acute respiratory urgency syndrome (ARDS), vasculitis and autoimmune inflammatory myitis.
JP2020550748A 2018-03-21 2019-03-20 Antibodies against signal regulatory protein α and methods of use Active JP7393342B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646210P 2018-03-21 2018-03-21
US62/646,210 2018-03-21
PCT/US2019/023238 WO2019183266A1 (en) 2018-03-21 2019-03-20 Antibodies against signal-regulatory protein alpha and methods of use

Publications (3)

Publication Number Publication Date
JP2021518142A JP2021518142A (en) 2021-08-02
JPWO2019183266A5 true JPWO2019183266A5 (en) 2022-03-24
JP7393342B2 JP7393342B2 (en) 2023-12-06

Family

ID=67987993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550748A Active JP7393342B2 (en) 2018-03-21 2019-03-20 Antibodies against signal regulatory protein α and methods of use

Country Status (17)

Country Link
US (2) US11292850B2 (en)
EP (2) EP3768314A4 (en)
JP (1) JP7393342B2 (en)
KR (1) KR20200133376A (en)
CN (1) CN112040979A (en)
AU (1) AU2019240111A1 (en)
BR (1) BR112020018927A2 (en)
CA (1) CA3094098A1 (en)
CL (2) CL2020002414A1 (en)
IL (1) IL277337A (en)
JO (1) JOP20200206A1 (en)
MA (1) MA52091A (en)
MX (1) MX2020009774A (en)
PE (1) PE20201265A1 (en)
PH (1) PH12020551391A1 (en)
RU (1) RU2020134294A (en)
WO (1) WO2019183266A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
BR112020018927A2 (en) 2018-03-21 2021-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGN REGULATORY PROTEIN AND METHODS OF USE
BR112021026376A2 (en) 2019-06-25 2022-05-10 Gilead Sciences Inc flt3l-fc fusion proteins and methods of use
PL4045083T3 (en) 2019-10-18 2024-05-13 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (en) 2019-10-31 2022-05-30 Forty Seven Inc Anti-cd47 and anti-cd20 based treatment of blood cancer.
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
US20230340112A1 (en) * 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
EP4139347A1 (en) * 2020-04-24 2023-03-01 Memorial Sloan Kettering Cancer Center Anti-cd3 antibodies and uses thereof
WO2022115767A1 (en) * 2020-11-30 2022-06-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of treating cancer
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
KR20240027677A (en) 2021-06-04 2024-03-04 베링거 인겔하임 인터내셔날 게엠베하 Anti-SIRP-alpha antibody
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 Diacylglycerol kinase modulating compounds
CN117355531A (en) 2021-06-23 2024-01-05 吉利德科学公司 Diacylglycerol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023028511A1 (en) * 2021-08-25 2023-03-02 Tallac Therapeutics, Inc. Sirp-alpha antibodies and conjugates
TW202330504A (en) 2021-10-28 2023-08-01 美商基利科學股份有限公司 Pyridizin-3(2h)-one derivatives
WO2023072217A1 (en) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Fusion proteins targeting cd3 and cd47
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
TW202400138A (en) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0710719T3 (en) 1990-01-12 2007-07-09 Amgen Fremont Inc Generation of xenogenic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
AU3457497A (en) 1996-06-17 1998-01-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel PTP20, PCP-2, BDP1, CLK and SIRP proteins and related products and method
US6143559A (en) 1996-11-18 2000-11-07 Arch Development Corporation Methods for the production of chicken monoclonal antibodies
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
EP1048299A1 (en) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
WO2001040307A1 (en) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antibodies against signal regulator proteins
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
EP2357187A1 (en) * 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2002315052A1 (en) 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2005014653A2 (en) 2003-02-28 2005-02-17 Protein Design Labs, Inc. Humanized chicken antibodies
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
HUE035250T2 (en) 2005-10-12 2018-05-02 Morphosys Ag Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EP2573112A1 (en) 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
ES2740823T3 (en) 2008-01-15 2020-02-06 Univ Leland Stanford Junior Methods for manipulating phagocytosis mediated by CD47
ES2796085T3 (en) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Stem cell markers of acute myeloid leukemia
EP2271657B1 (en) 2008-03-04 2017-03-01 Crystal Bioscience Inc. Gel microdrop composition and method of using the same
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2770825A1 (en) 2009-08-13 2011-02-17 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal cdrs
US9151760B2 (en) 2009-09-29 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
CN103189502A (en) 2010-08-27 2013-07-03 大学健康网络 Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on sirpa expression
EP2713712B1 (en) 2011-05-24 2017-04-12 Crystal Bioscience Inc. Transgenic chicken comprising an inactivated immunoglobulin gene
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013059159A1 (en) 2011-10-21 2013-04-25 Crystal Bioscience, Inc. In vivo method for generating diversity in a protein scaffold
EP4372081A2 (en) 2011-12-30 2024-05-22 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
WO2014071397A2 (en) 2012-11-05 2014-05-08 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
HUE058790T2 (en) 2012-12-17 2022-09-28 Pf Argentum Ip Holdings Llc Treatment of cd47+ disease cells with sirp alpha-fc fusions
DK3311824T3 (en) 2013-02-05 2020-04-14 Univ Leland Stanford Junior CD47 TARGETED TREATMENTS FOR THE TREATMENT OF INFECTIOUS DISEASES
EP2970493B1 (en) 2013-03-15 2019-04-03 The Board of Trustees of the Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
EP2992089B1 (en) 2013-04-29 2021-09-08 The Board of Trustees of the Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
US10329354B2 (en) 2013-09-18 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
CN106456748A (en) 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 Targeted therapy for small cell lung cancer
CA2939293C (en) 2014-03-11 2023-10-03 The Board Of Trustees Of The Leland Standford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
TWI702228B (en) 2014-08-08 2020-08-21 美商Ａｌｘ腫瘤技術股份有限公司 Sirp-alpha variant constructs and uses thereof
EP3643727A1 (en) 2014-08-15 2020-04-29 Merck Patent GmbH Sirp-alpha immunoglobulin fusion proteins
EP4257145A3 (en) 2014-08-26 2023-10-18 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
ES2901501T3 (en) 2015-01-21 2022-03-22 Univ Leland Stanford Junior Use of TLR agonists and anti-CD47 agent to enhance phagocytosis of cancer cells
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
MX2018001182A (en) 2015-07-28 2018-04-20 Univ Pennsylvania Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof.
AU2016310348B2 (en) 2015-08-26 2023-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
EP4186927A1 (en) 2015-10-21 2023-05-31 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
CN115569192A (en) 2015-12-11 2023-01-06 小利兰·斯坦福大学托管委员会 Treatment of cancer with dual targeting of CD47 and EGFR
WO2017180519A1 (en) 2016-04-10 2017-10-19 George State University Research Foundation, Inc. Methods for treating cancer and inhibiting graft rejection
WO2017178653A2 (en) * 2016-04-14 2017-10-19 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
KR102355240B1 (en) 2016-04-14 2022-01-25 오제 이뮈노테라프틱스 Novel anti-SIRPa antibodies and methods of their therapeutic application
US20190153095A1 (en) 2016-07-05 2019-05-23 National University Corporation Kobe University Antitumor Agent
CA3031034A1 (en) 2016-08-03 2018-02-08 The Board Of Trustees Of The Leland Stanford Junior University Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
CN110325549B (en) 2016-12-09 2024-03-08 艾利妥 anti-SIRP alpha antibodies and methods of use thereof
AU2018213397A1 (en) 2017-01-30 2019-07-25 The Board Of Trustees Of The Leland Stanford Junior University A non-genotoxic conditioning regimen for stem cell transplantation
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
TWI710574B (en) 2017-05-16 2020-11-21 荷蘭商拜恩迪斯公司 ANTI-SIRPα ANTIBODIES
PL3658589T3 (en) 2017-07-26 2024-03-18 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
BR112020018927A2 (en) 2018-03-21 2021-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGN REGULATORY PROTEIN AND METHODS OF USE
WO2019226973A1 (en) 2018-05-25 2019-11-28 Alector Llc Anti-sirpa antibodies and methods of use thereof
AU2019302152A1 (en) 2018-07-10 2021-01-07 Daiichi Sankyo Company, Limited Anti-sirpalpha antibody
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2020102422A1 (en) 2018-11-14 2020-05-22 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
SG11202104431PA (en) 2018-11-15 2021-05-28 Byondis Bv HUMANIZED ANTI-SIRPα ANTIBODIES

Similar Documents

Publication Publication Date Title
JPWO2019183266A5 (en)
RU2020134294A (en) ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS FOR THEIR APPLICATION
Labrijn et al. Bispecific antibodies: a mechanistic review of the pipeline
Li et al. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
JP7174522B2 (en) Chimeric antigen receptor targeting Fc receptor-like 5 and uses thereof
Maher Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
JP2023091037A (en) Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
JP2021063082A5 (en)
AU2019243448B2 (en) Guidance and navigation control proteins and method of making and using thereof
JP2018525382A5 (en)
JP2020503057A5 (en)
Chen et al. Bispecific antibodies in cancer immunotherapy
JP2019525771A5 (en)
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
US20180021418A1 (en) Engineered t cells and uses therefor
HRP20221323T1 (en) Antibodies against signal-regulatory protein alpha and methods of use
JP7399852B2 (en) Multispecific antibodies and their production and use methods
CN110891650A (en) Guidance and navigation control proteins and methods of making and using same
CN110799540A (en) Multispecific antibodies and methods of making and using the same
KR20230129983A (en) Targeted cytokine constructs for engineered cell therapy
WO2023020423A1 (en) Ror1 car or ror1 /cd19 dual car t cells for the treatment of tumors
CA3155728A1 (en) Trivalent binding molecules
WO2019032699A1 (en) Cells expressing cell surface receptors and antibodies
Cortés-Hernández et al. Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: An overview
JPWO2019200007A5 (en)